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Background
Tuberculosis (TB) is one of the top three global causes of infec-
tious diseases and one of the top ten global causes of death, recently 
surpassing even HIV/AIDS1. Treatment of drug sensitive TB 
(DS-TB) is long, typically requiring six months with good adher-
ence to achieve cure and prevent relapse after therapy is stopped. 
However, treatment adherence and completion rates are not opti-
mal, which could probably be improved by shorter and more 
effective treatments. Multiple studies conducted over the past 40 
years have attempted to reduce the treatment duration of TB. In 
the 1970s, successful combination chemotherapy lasted 24 months, 
based on a series of studies conducted by the British Medical 
Research Council (BMRC). Follow-up studies in the early 1980s 
successfully reduced treatment duration to 6 months using pyrazi-
namide and rifampin, achieving relapse rates of 1–2%. Trials that 
reduced the duration to below 6 months experienced increasing 
relapse rates, roughly 12% at 4 months and up to 20% at 3 months2, 
establishing 6 months as the accepted treatment duration for all 
cases of DS-TB.
Three recent randomized-controlled trials attempted to shorten 
treatment using a 4-month experimental arm with a fluoroqui-
nolone substituted for one of the four standard drugs3–5. In all three 
trials, the 4-month treatment arms had relapse rates of approxi-
mately 15–20%, significantly higher than the standard of care 
6-month arms but similar to the BMRC 4-month treatment trials 
(12%, 95% CI 9-16 among 364 patients) conducted 30+ years 
earlier2. These trials suggest that, with currently available drugs, 
roughly 80–85% of drug-sensitive TB patients are cured with 
4 months of standard therapy but 15–20% will relapse if not treated 
for at least 6 months and, further, that a subset of those with less 
severe disease could be cured at 4 months. Identifying this sub-
set prospectively could lead to: (1) new treatment guidelines for 
eligible lower risk patients; (2) criteria for selection of high-risk 
patients that might be candidates for Phase 2b studies with novel 
regimens with proposed shorter durations; and (3) quantitative 
estimates of the rate of change of markers associated with dura-
ble cure at specific timepoints to establish milestones for even 
shorter regimens. The hypothesis that patients with less severe 
disease can be cured earlier was tested in a separate treatment 
shortening trial, in which only those with less severe disease and 
good initial treatment response were randomized to 4 vs. 6 months 
of treatment6. In this trial, less severe disease was defined as 
absence of pulmonary cavities on baseline chest x-ray, and good 
treatment response was defined as sputum culture conversion to 
negative by 2 months of treatment. Only participants who met 
these 2 criteria were randomized to 4 vs. 6 months of treatment 
with standard of care drugs. This trial was stopped early by its 
Data and Safety Monitoring Board (DSMB) because those in the 
6-month arm had a relapse rate of 1.6% while the 4-month arm 
had a significantly higher relapse rate of 7% (P<0.01). Despite this 
trial not meeting its target, the disease stratification criteria did 
increase the treatment success rate of the 4-month arm from 
80–85% in the prior non-stratified trials to 93% (95% CI 89%, 
96%), approaching 6-month treatment relapse rates. If the strati-
fication criteria could be further refined, a successful 4-month 
treatment arm may be feasible. The hypothesis of the Predict 
TB trial is that a combination of radiographic characteristics at 
baseline, the rate of change of these features at one month, and 
markers of residual bacterial load at 4 months will identify patients 




This is a prospective, multicenter, randomized, phase 2b, nonin-
feriority clinical trial of pulmonary DS-TB participants conducted 
at 4 sites in Henan Province, China (Henan Provincial Chest 
Hospital, Xinmi City Institute of Tuberculosis Prevention and 
Control, Kaifeng City Institute of Tuberculosis Prevention and 
Control, and Zhongmu County Health and Epidemic Preven-
tion Station) and 5 sites in and around Cape Town, South Africa 
(Stellenbosch University, University of Cape Town Lung Insti-
tute, University of Cape Town South African Tuberculosis Vaccine 
Initiative, Khayelitsha Site B, and TASK Applied Science). 
Inclusion criteria are:
1)  Age 18 to 65 years, with body weight from 35 kg to 90 kg
2)  Not been treated for active TB within the past 3 years
3)  Not yet on TB treatment
4)  Xpert positive for Mycobacterium tuberculosis
5)   Rifampin-sensitive pulmonary tuberculosis as indicated by 
Xpert
6)   Laboratory parameters within previous 14 days before 
enrollment: 
a.   Serum AST and ALT <3x upper limit of normal 
(ULN)
b.   Creatinine <2x ULN
c.   Hemoglobin >7.0 g/dL
d.   Platelet count >50 x109 cells/L
7)    Able and willing to return for follow-up visits
8)    Able and willing to provide informed consent to participate 
in the study
9)    Willing to undergo an HIV test
10) Willing to have samples, including DNA, stored
11)  Willing to consistently practice a highly reliable, non- 
hormonal method of pregnancy prevention (e.g., 
condoms) during treatment if participant is a premenopau-
sal female, unless she has had a hysterectomy or bilateral 
tubal ligation or her male partner has had a vasectomy
Exclusion criteria are:
1)   Extrapulmonary TB, including pleural TB
2)    Pregnant or desiring/trying to become pregnant in the next 
6 months or breastfeeding
3)   HIV infected
4)   Unable to take oral medications
5)    Diabetes as defined by point of care HbA1c ≥6.5%, 
random glucose ≥200 mg/dL (or 11.1 mmol/L), fasting 
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plasma glucose ≥126 mg/dL (or 7.0 mmol/L), or the 
presence of any anti-diabetic agent (including traditional 
medicines) as a concomitant medicine
6)    Disease complications or concomitant illnesses that may 
compromise safety or interpretation of trial endpoints, 
such as known diagnosis of chronic inflammatory condi-
tion (e.g. sarcoidosis, rheumatoid arthritis, connective tis-
sue disorder)
7)    Use of immunosuppressive medications, such as TNF-
alpha inhibitors or systemic or inhaled corticosteroids, 
within the past 2 weeks
8)   Use of any investigational drug in the previous 3 months
9)    Substance or alcohol abuse that in the opinion of the inves-
tigator may interfere with the participant’s adherence to 
study procedures
10)  Any person for whom the physician feels this study is not 
appropriate 
Eligible participants who sign the informed consent are started 
on standard of care treatment with fixed-dose combination tablets 
composed of isoniazid (H), rifampin (R), pyrazinamide (Z), and 
ethambutol (E) during the initial 8-week intensive phase and 
HR during the subsequent continuation phase, using national 
weight-based guidelines (Table 1). PET/CT scans are done at 
baseline, week 4, and either week 16 or 24. Participants are fol-
lowed through month 18 and a fourth PET/CT scan is done if 
recurrent TB develops during follow-up. All PET/CT scans are 
read by 2 readers using MIM Software (v. 6.6 or higher, MIM 
Software Inc, Cleveland, Ohio, USA). Scans with discrepant arm 
assignments by the initial 2 readers are read by a third reader. 
All PET/CT scan readers underwent a prequalification training 
process with 15 practice baseline and week 4 scans to ensure 
consistency among all readers in how the scans are read (see 
Supplementary File 5 for PET/CT reading SOP). The practice 
PET/CT scans were obtained from a previously conducted 
study at Stellenbosch University funded by the Bill and Melinda 
Gates Foundation (Mycobacterium tuberculosis biomarkers for 
diagnosis and cure, OPP51919).
Participants are stratified into treatment arms by the early treat-
ment completion criteria, composed of baseline PET/CT criteria, 
the change in these measurements at week 4, and a minimum 
adherence dose count and Xpert cycle threshold as a marker 
of residual sputum bacterial load at week 16 (Table 2). Those 
with more severe disease (who do not meet all early treatment 
completion criteria) are placed in Arm A (standard of care arm, 
treatment completion at week 24). Those with less severe dis-
ease (who meet all early treatment completion criteria) are rand-
omized either to Arm B (standard treatment duration of 24 weeks) 
or Arm C (standard treatment shortened to 16 weeks) at week 16. 
The third PET/CT scan is done at week 16 for participants in 
Arms B or C and randomized to either week 16 or 24 for par-
ticipants in Arm A. All participants are followed to week 72 for 
final treatment outcomes (Figure 1), with sputum, blood, and urine 
samples collected per the schedule in Table 3. Study enrollment 
began in Cape Town in June 2017 and is expected to begin in Henan 
in October 2017. Enrollment is expected to take about 3 years and 
the study is expected to complete within 5 years.
Treatment adherence
Total treatment duration will be determined by dose counts. Par-
ticipants will receive either 16 weeks of treatment (Arm C) or 
24 weeks of treatment (Arms A and B). (Arm A participants 
may be treated longer at the discretion of the treating physician.) 
Participants receiving 16 weeks of treatment will receive 
112 doses with a minimum total of 100 doses. Participants who 
do not meet this minimum dosing requirement within the week 
Table 1. Adult weight-based dosing guidelines for intensive phase and continuation 
phase TB treatment using fixed-dose combination (FDC) tablets by country. These are 
the dosing guidelines used in the Predict TB study and are taken from the South African 
national TB guidelines39 and the Chinese fixed drug combination tablet package insert from 
the Shenyang Hongqi Pharmaceutical Company, Ltd.
Intensive Phase (initial 8 weeks) Continuation Phase (weeks 9–24)
HRZE (75/150/400/275 mg) HR (75/150 mg) HR (150/300 mg)
Weight China and South Africa South Africa
30–37 kg 2 tablets daily 2 tablets daily --
38–54 kg 3 tablets daily 3 tablets daily --
55–70 kg 4 tablets daily -- 2 tablets daily
>70 kg 5 tablets daily -- 2 tablets daily
China
<50 kg -- individual drug tablets (non-FDC)
≥50 kg -- 2 tablets daily
Note: H=isoniazid; R=rifampin; Z=pyrazinamide; E=ethambutol
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Table 2. Predict TB early treatment completion criteria. These are the criteria used at 
baseline, week 4, and week 16 to stratify enrolled participants to Arm A or Arm B vs C. 
Participants must meet all criteria to be eligible for randomization to Arm B vs C at week 





    •  No total lung collapse of a single side, AND 
    •  No pleural effusion, AND 
    •  No single cavity air volume on CT scan >30 mL, AND 
    •  CT scan hard volume (-100 to +100 HU density) <200 mL, AND 
    •  PET total activity <1500 units 
Week 4 PET/CT:
    •   All individual cavities decrease by >20% (unless cavity <2 mL), 
AND
    •   CT scan hard volume does not increase by >10% unless the 
increase is <5 mL, AND
    •   PET total activity does not increase by >30% unless the 
increase is <50 units
Bacterial load 
criterion
Week 16 Xpert cycle threshold ≥30
Adherence 
criterion
Minimum of 100 doses received by week 16
Figure 1. Predict TB study schematic.
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16 visit window will not be eligible for randomization and will 
be moved to Arm A. Approximately 90% adherence is used, as 
missing more than this has been associated with an increased 
risk of poor outcomes7. Participants receiving 24 weeks of treat-
ment will receive 168 doses with a minimum total of 150 doses. 
Missed doses during the initial 8-week intensive phase will be 
added on to the end of the intensive phase, replacing continuation 
phase dosing. Arm B participants who do not achieve the mini-
mum 150 doses within the Week 24 visit window will be 
allowed to complete a minimum of 150 doses even if this exceeds 
the visit window.
All possible and available forms of adherence monitoring are 
encouraged as much as local resources allow. This includes (but 
does not require) directly observed therapy (DOT), whether by a 
healthcare worker, an outreach worker, or a family member. The 
vast majority of participants will not receive formal DOT; these 
participants will be provided an electronic pill box, the Medica-
tion Event Reminder Monitor (MERM; Wisepill Technologies, 
South Africa), which has been shown to improve treatment adher-
ence among TB patients in China8. The MERM is a box that stores 
dispensed medication and also contains a cartridge that monitors 
box openings and sounds an alarm daily at a set time to remind 
participants to take their medicine. Box open/close data will be 
downloaded on follow-up visits.
Treatment outcome definitions
Treatment success is defined as a participant with at least 2 con-
secutive negative cultures on solid medium over a span of at least 
4 weeks, achieved by the end of therapy, with no subsequent 
confirmed positive cultures during follow-up. Participants who 
remain culture positive on solid medium at Week 24 in Arm A 
will be considered treatment failures, will be taken off study as 
meeting a study endpoint and referred to continue treatment per 
the local standard of care (SOC). Participants who convert to solid 
culture negative who subsequently have a single solid culture 
positive for Mtb before or at week 24 need to have a subsequent 
culture positive for Mtb to be confirmed as treatment failures. 
Isolated positive cultures that are not confirmed on a subsequent 
sputum sample are not considered failures as these may have 
arisen from processing error or laboratory contamination9. Solid 
culture results will be used for the primary endpoint analysis. 
Liquid culture results may be used for secondary analyses.
Participants randomized to Arms B or C who are subsequently 
found to have a positive culture for Mtb on solid medium 
from weeks 16–24, confirmed on a subsequent culture, will be 
considered treatment failures. These participants will be referred 
to continue treatment per local SOC and will be followed obser-
vationally until the end of their treatment to determine outcomes. 
Participants who convert their sputum to culture negative (2 con-
secutive negatives over ≥4 weeks) and who subsequently become 
culture positive for Mtb again on solid medium during follow-up 
after week 24, confirmed by a second positive sputum culture, 
will be considered recurrences. Isolated positive cultures that are 
negative on follow-up will not be considered recurrences. 
Relapses will be distinguished from re-infections by DNA strain 
typing and only relapses will be considered a study endpoint. 
Participants who are treatment failures and relapses will have 
drug sensitivity testing done to inform subsequent treatment. 
Relapses on Arms B and C will have observational follow-up until 
the end of retreatment to determine outcomes. 
Statistical analyses
This is a non-inferiority study, with the primary endpoint being a 
comparison of the rate of treatment successes at 18 months (after 
treatment initiation) between Arms B and C. Final study treat-
ment outcome data from participants who are unable to return at 
18 months but do return during the 1 year following will be 
imputed back to the 18-month time point for the primary endpoint. 
The primary analysis will estimate the lower bound of a 95% 
confidence interval of the difference in success rates between 
arms B and C. If the lower bound is greater than -7%, this will 
be evidence that the treatment-shortening arm is not inferior to the 
standard duration arm. Confidence intervals will be constructed 
using Wald intervals, with inverse weighting according to site- 
estimated variances, as a stratified analysis. Additional analyses 
of the primary endpoint will consider a non-stratified-based 
confidence interval of the difference.
The sample size is determined for the comparison between Arms 
B and C. Because these are lower risk participants, we expect 
a treatment success rate of 97%. Table 4 provides power cal-
culations for a total enrollment of 117 and 140 per group. With 
true success rates of 97% in both arms, study power is greater 
than 90% with only 117 participants per group. However, to 
increase power to accommodate a scenario in which the true 
success rate in the four-month treatment arm is slightly lower 
than the six-month arm, a sample size of 140 per treatment arm 
was selected, corresponding to 155 subjects per arm after adjust-
ing for a 10% loss to follow-up. We expect that approximately 
50% of participants will be classified as higher risk and be 
placed into Arm A, giving a total study sample size of 620 
participants.
PK-MIC substudy
Typically, bacteria are termed “resistant” to a drug if the bacteria 
are able to grow at concentrations above the established “break-
point” for that drug and resistance is a well-known determinant 
of TB treatment outcome10. Conventional drug susceptibility test-
ing for isoniazid and rifampin will be employed during the trial 
to confirm that patients have susceptible isolates. The minimum 
inhibitory concentration (MIC) for a specific bacterial isolate is 
the drug concentration at which the growth of the bacteria is inhib-
ited by approximately 95%. For each patient enrolled into the sub-
study, we will determine the specific isoniazid and rifampin MIC 
for their Mtb isolate. In addition, TB patients are known to have 
widely variable serum PK values, and these differences appear 
to affect treatment outcome11–13. Because a given patient’s serum 
drug concentration achieved will affect the clinical interpretation 
of a given MIC result, we hypothesize that a model incorporating 
both of these parameters may predict outcomes better than either 
one alone. This hypothesis will be tested in a substudy among 
study participants believed to be at higher risk of relapse based on 
preliminary data, those who move to Arm A due to an inadequate 
treatment response on the week 4 PET/CT scan. After substudy 
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informed consent is signed, two substudy visits will occur where 
a baseline blood sample is drawn, TB medication for that day is 
dosed, then blood is again drawn at 1, 2, and 6 hours post-dose 
for pharmacokinetic (PK) analysis for isoniazid and rifampin. 
For every Arm A participant who agrees to join the substudy, a 
control participant from the combined B/C arm will also be 
recruited to join. This will be a convenience sample of participants 
willing to participate in the substudy and no specific sample size is 
targeted.
Data and Safety Monitoring Board (DSMB)
The standing NIAID DSMB with three global TB experts added 
as ad hoc members will provide oversight of the study. The DSMB 
will meet at least twice per year to evaluate safety, study conduct, 
and scientific validity and integrity of the trial. 
Ethical statement
Informed consent is conducted in the local language of the 
participant (Chinese, English, Afrikaans, or Xhosa). The study 
radiation dose was reviewed and approved by the Radiation 
Safety Committee of the U.S. National Institutes of Health (NIH). 
The study protocol was reviewed and approved by the institu-
tional review board (IRB) of the National Institute of Allergy and 
Infectious Diseases (NIAID), NIH (085315; most recent approval 
numbers listed here and below, Henan sites do not use approval 
numbers) and all local IRB/ethics committees (Henan Provincial 
Chest Hospital [HPCH], Henan Center for Disease Control [Henan 
CDC], Stellenbosch University (M16/08/031, M16/10/039), and 
the University of Cape Town (645/2016, 646/2017, 647/2016)), as 
well as the South African Medicines Control Council.
Discussion
With currently available drugs for TB, all published trials 
attempting to shorten TB treatment below 6 months have failed. 
The trial that came closest to success randomized only those with 
less severe disease and favorable early treatment response (base-
line chest x-ray without cavity and a month 2 sputum culture 
that had converted to negative). Multiple tuberculosis biomarkers 
potentially predictive of treatment outcomes are being studied to 
improve the risk stratification of patients14. From a microbiologi-
cal standpoint, sputum culture conversion at 2 months of treat-
ment is most commonly used to predict non-relapsing cure15 but 
its true predictive ability is poor, with one meta-analysis show-
ing a pooled sensitivity and specificity for predicting relapse 
of 40% (95% CI 25%-56%) and 85% (95% CI 77%-91%), 
respectively16. A review of data from the BMRC trials from the 
1970s and 1980s found only a weak correlation (R2=0.36) for 
this marker as a surrogate for treatment failure and relapse, depend-
ing on factors such as geographic location, baseline disease and 
cavity status, and concomitantly used medications17. Further 
evidence against using culture conversion as a surrogate for predict-
ing treatment outcome was recently demonstrated from the phase 
3 TB treatment shortening trial REMoxTB4, where subsequent 
analyses of the culture data collected demonstrated poor correla-
tion with treatment outcome whether analyzed at a single time point 
(2 months) or over time (time to culture conversion or time to 
culture positivity)18.
The ability of early radiographic changes to predict subsequent 
treatment outcomes in TB has been recognized for over 50 years19 
and prior studies have identified baseline cavity on chest x-ray 
as a risk factor for relapse20–22. However, chest x-rays are not 
sensitive for cavities, particularly smaller ones; more recent 
analyses of radiographic biomarkers have moved beyond chest 
x-ray to 2-deoxy-2-[18F]-fluoroglucose (FDG) positron emis-
sion tomography/computed tomography (PET/CT) as an early 
marker of treatment response and possibly as a marker for relapse 
at the end of treatment. CT scans produce more detailed lung 
morphology than chest x-rays and PET scans provide additional 
information on inflammatory activity. In macaques, changes on 
PET/CT scans correlate with TB disease activity and treatment 
response23,24. Our group has analyzed human PET/CT data from 
a randomized clinical trial using metronidazole in the treat-
ment of pulmonary multi-drug resistant tuberculosis (MDR-TB) 
participants25. As a substudy within the overall MDR-TB study, 
we performed PET/CT scans at 0 and 2 months and CT scans 
at 0, 2, and 6 months of treatment and correlated these changes 
with final treatment outcomes 30 months after treatment start 
(6 months after the end of therapy). PET changes at 2 months 
and CT changes at 6 months appeared to be more sensitive to 
predict final treatment outcomes than sputum culture conversion 
Table 4. Sample size power calculations for the Predict TB trial. 
Power calculations are shown for total sample sizes of 117 and 140 
per group (Arms B and C) for different success rates across and 
between treatment arms. Because these are lower-risk participants, 
a 97% success rate was targeted. A sample size of 140/arm 
was selected to increase power in case the shortened treatment 
arm has a slightly lower success rate. This sample size was then 
increased by 10% to 155/arm to account for those lost to follow-up.
Success rate by study 
arm
Power for concluding NI with 7% 









0.99 0.99 0.999 1
0.99 0.98 0.984 0.994
0.99 0.97 0.863 0.912
0.98 0.98 0.985 0.994
0.98 0.97 0.903 0.942
0.98 0.96 0.726 0.792
0.97 0.97 0.932 0.963
0.97 0.96 0.803 0.862
0.97 0.95 0.621 0.689
0.96 0.96 0.862 0.911
0.96 0.95 0.716 0.782
0.96 0.94 0.545 0.609
0.95 0.95 0.792 0.851
0.95 0.94 0.644 0.711
0.95 0.93 0.487 0.547
Page 10 of 23
Gates Open Research 2017, 1:9 Last updated: 12 JAN 2018
at 2 months, although these differences were not statistically 
significant26. These results support the potential of PET/CT 
imaging biomarkers as possible surrogate endpoints in clinical 
trials, and larger cohorts are needed to confirm these results.
We developed the radiographic early treatment completion cri-
teria for the Predict TB trial (Table 2) (unpublished study; 
National Institutes of Health, Bethesda, MD, USA) using a 
cohort of 100 pulmonary DS-TB participants from Cape Town 
who received PET/CT scans at baseline, 1 month, and 6 months 
while on standard therapy through the national TB treatment 
program27. The participants were treated for 6 months, then fol-
lowed through 18 months for final treatment outcomes. In total, 
92 participants had complete PET/CT scan data, Xpert MTB/RIF 
cycle thresholds, and treatment outcomes. After 18 months of 
follow-up, 73 were considered cured, 8 failed treatment, and 
11 were restarted programmatically on TB treatment, defined as 
the participant restarting treatment during follow-up for any rea-
son. Our radiographic early treatment completion criteria are 
divided into baseline disease burden and week 4 reduction in 
disease burden due to treatment, which is reflective of the 
Johnson 2009 study which also had a measure of baseline dis-
ease burden (baseline chest x-ray without cavity) and treatment 
response (month 2 sputum culture conversion).
Currently, the only direct measure of TB sputum bacterial load 
is sputum smear, which is not very sensitive. Alternative surro-
gate markers evaluated include the time to positivity (TTP) of a 
positive culture on liquid mycobacterial culture systems, with the 
shorter TTP indicating a higher bacterial load. Different studies 
have demonstrated some correlation between Mycobacteria 
Growth Indicator Tube (MGIT) TTP and sputum bacterial load 
but with poor specificity in predicting treatment outcomes28,29. 
Thus, although time to culture conversion and MGIT TTP do 
correlate independently with treatment outcome, these markers 
do not discriminate well between high and low risk patients and 
therefore have only a limited role in predicting treatment out-
comes of individual patients18. Another marker of sputum bac-
terial load is the GeneXpert cycle threshold. The GeneXpert 
assay is an automated rapid molecular diagnostic test for Mtb 
and resistance to rifampin with results provided directly from 
sputum within 2 hours30. The test is run using a polymerase 
chain reaction and the number of cycles (cycle threshold) at 
which the amplification curve crosses the specified thresh-
old is recorded, with a lower cycle threshold suggestive of a 
higher bacterial load. Three studies have correlated Xpert MTB/
RIF cycle threshold with sputum smear status, with varying 
sensitivity and specificity levels depending on the cycle 
threshold cut point used31–34. A fourth study found that Xpert 
MTB/RIF results correlated with smear grades, solid culture 
results, and liquid culture TTP (all p<0.0001) but Xpert MTB/RIF 
sputum positivity rates declined more slowly during treatment 
than sputum smear and culture results. Using the combined 
binary smear and culture results as a reference standard, sensi-
tivity of Xpert MTB/RIF was excellent at 97.0% (95% CI 95.8-
97.9) but specificity was poor at 48.6% (95% CI 45.0-52.2) as the 
assay is unable to differentiate viable, dormant, and non-viable 
Mtb bacteria35.
In the study mentioned previously of 100 pulmonary DS-TB 
participants in Cape Town, a week 24 Xpert MTB/RIF cycle 
threshold of ≥30 predicted treatment failure with higher sensitiv-
ity and specificity than earlier time points36. This is in contrast 
to the week 8 culture, which has lower sensitivity (for cure) than 
Xpert MTB/RIF cycle threshold at week 24: 61% (week 8 cul-
ture) vs 89% (Xpert MTB/RIF cycle threshold week 24, p<0.01). 
Estimates of specificity (for failure) for Xpert MTB/RIF cycle 
threshold week 24 was higher than week 8 culture (88% vs 50%), 
but the improvement was not statistically significant. The poor 
performance of week 8 culture data as a predictor of treatment 
outcome is similar to what was observed in the REMoxTB 
trial18.
The observation that a later test predicts outcomes better than an 
earlier test may be similar to findings in HIV infection, where 
baseline CD4 cell count is a strong predictor of mortality over 
time but current CD4 cell count is even stronger37. This has 
been seen in TB too, where culture conversion status at month 
6 predicts final treatment outcome significantly better than cul-
ture conversion status at month 238. Taken together, these results 
suggest that Xpert MTB/RIF cycle thresholds collected later may 
be able to replace an earlier microbiological culture in predicting 
treatment outcomes, with the major advantage of Xpert MTB/RIF 
over culture being the time to test result, with Xpert requiring 
2 hours and culture up to 6 weeks. Thus, Xpert cycle threshold 
may be useful as a point-of-care test whereas culture cannot.
In summary, the Predict TB trial builds upon previous trial 
results, in particular the Johnson 2009 trial6. Instead of using a chest 
x-ray to determine baseline disease burden, we will use a PET/CT 
scan. Instead of using month 2 culture conversion as a measure of 
treatment response, we will use month 1 change in PET/CT scan 
disease burden and a month 4 Xpert MTB/RIF cycle threshold. 
Prior treatment shortening trials that randomized all subjects to 
shortened vs. standard treatment achieved treatment success rates 
in the 4-month arms of roughly 80–85%. Using a risk stratifica-
tion approach, the Johnson study increased this to 93%. By refining 
their risk stratification parameters, we hypothesize that the treat-
ment success rate in our 4-month arm will be non-inferior to our 
6-month arm. If successful, our methodology could be extended 
to identify participants cured with even shorter regimens. We do 
not expect that PET/CT scans will become a risk stratification tool 
for global TB use due to its cost and availability limited to larger 
cities. Use of PET/CT scans would likely be limited to clinical 
trials but could be a method to stratify trial participants and 
possibly become a surrogate endpoint by which to reduce the 
number of participants needed in a Phase 2b trial, shorten overall 
trial duration or predict drug sterilizing activity such as in early 
bactericidal activity studies. These achievements could expand 
the number of regimens evaluated in Phase 2b trials prior to 
committing to an expensive and time-consuming Phase 3 study and 
thereby contribute to the likelihood of identifying optimal regi-
mens. If the Predict TB trial is successful, other immunological 
biomarkers or transcriptional signatures that correlate with 
treatment outcome may be identified. These markers or signa-
tures will likely be much cheaper and more widely available than 
PET/CT scans and more amenable to being scaled up globally.
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The method of randomization is described in the statistical analysis plan, although it is
our practice to keep precise details (e.g., block size) restricted. In brief, participants who
meet baseline, week 4, and week 16 early completion criteria are block randomized
(stratified by site) to Arm B (continue treatment to week 24) or Arm C (complete treatment
early at week 16). 
       2. Are PET/CT readers blinded to the patient randomization?
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For randomization to either arm B or C, blinding is not a concern, as patient randomization
does not occur until after the reader scores are entered into the database. Indeed, these
results are needed to determine risk classification, which determines eligibility for
randomization. Furthermore, PET/CT readers are blinded to other reader’s results.
The other randomization element in this study occurs amongst arm A participants. The
timing of imaging scans for arm A participants is randomized to either 16 or 24 weeks. 
PET/CT readers are not blinded to the timing of the scan. 
The range of weight in inclusion criteria is broad – this could further be noted in the PK-MIC
substudy.
This will be noted in future publications related to the PK-MIC substudy.
      3. Please consider adding additional info on analysis of PK samples (location, methods etc).
In Cape Town, PK sample analysis will be performed on plasma samples shipped to the
Rutgers New Jersey Medical School in Newark, New Jersey, USA. In China, PK sample
analysis will be performed on plasma samples shipped to Shanghai Public Health Clinical
Center in Shanghai. The samples will be analyzed by high pressure liquid
chromatography coupled to a tandem mass spectrometer as previously described (
. 2012 Jan; 56(1): 446–457. Antimicrob Agents Chemother doi:  10.1128/AAC.05208-11).
The equipment and methods used by the two labs are harmonized currently and will be
revalidated as producing similar results prior to protocol sample analysis. Data











Our decision to use a week 4 PET/CT scan was based primarily on data from reference 27
which concerned drug-sensitive patients; the 8-week changes in reference 26 were in
MDR patients. The overall slower response in MDR patients compared to drug susceptible
patients suggests that a similar outcome-predictive timepoint would be shorter than 8
weeks. Therefore, we chose to use the 4-week changes in drug susceptible patients for
this study. Although inflammation is still ongoing at week 4 compared to later time points,
there appeared to be enough change from baseline to week 4 to be predictive of final
treatment outcomes. Later time points may have less inflammation and possibly be more
predictive but a certain amount of inflammation still persists even 1 year after completion
of treatment in apparently cured patients, as noted in ref 27. Our goal therefore was to
identify an early time point that was still predictive of final treatment outcomes. We
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identify an early time point that was still predictive of final treatment outcomes. We
hypothesized that a week 4 scan would accomplish this. 
 NoneCompeting Interests:
 01 December 2017Referee Report
doi:10.21956/gatesopenres.13810.r26111
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Our goal is to include participants with a wide range of TB disease severity. Hence, we
use GeneXpert positive as an inclusion criterion regardless of smear status. We do collect
enrollment smear status so this can be analyzed. For GeneXpert cycle threshold, the









We agree that studying the differences in HIV positive vs negative TB patients is critically
important. However, for this initial proof-of-concept trial, we were unsure of the possible
confounding effect that HIV infection might have on PET/CT scanning response and
immunological and other biomarker responses. Thus, for this initial study, we elected to










Detailed adherence data will be collected at every visit while the participant is on




Solid medium was selected as the primary endpoint to reduce variability associated with
false positive liquid culture results possibly due to laboratory cross-contamination. We
note that the reviewer’s recent publication (Phillips et al. BMC Medicine (2017) 15:207)
comparing solid vs. liquid culture results from the REMoxTB trial found that such
laboratory cross-contamination did sometimes occur, although additional factors also
may have played a role. Using liquid culture results as the primary endpoint would also




Participants who default will not be eligible for randomization. Participants who are
randomized but then have a single positive culture on their last visit and cannot be
3,4
5
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randomized but then have a single positive culture on their last visit and cannot be
brought back for a confirmatory culture will have their single positive culture strain typed.
If the strain type is consistent with their original TB strain, this participant will be
classified as “unfavorable.” If the strain type is consistent with a new TB infection, the
participant will be classified as “favorable.”
How will other patients who are lost are during treatment be classified? Unassessable or
unfavourable? Will those lost during follow-up be regarded as unassessable in the analysis?
As indicated above, participants who are lost during treatment, are not eligible for
randomization and will not be included in the primary analysis. Participants lost during
follow-up will be considered “unassessable” for the primary analysis. The number of
randomized participants who are lost during follow-up is anticipated to be small, given the
eligibility requirements for randomization. However, this will be closely monitored during
the study. Additionally, sensitivity analyses will evaluate the impact of considering these
as unassessable considering the time at which the participant was lost to follow-up and
 their status at that time.
 None.Competing Interests:
 27 November 2017Referee Report
doi:10.21956/gatesopenres.13810.r26114
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Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Partly
 No competing interests were disclosed.Competing Interests:
We have read this submission. We believe that we have an appropriate level of expertise to



















In RSA, staff from the local TB clinics are aware of the study inclusion/exclusion criteria
and refer newly diagnosed pulmonary TB patients who appear to fit the criteria to study
staff for informed consent and screening. In China, local TB clinic staff are our study staff
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staff for informed consent and screening. In China, local TB clinic staff are our study staff
and evaluate newly diagnosed TB patients for study eligibility. Those who appear eligible
are asked to sign study informed consent for formal study screening.
There should be some statement about the qualification or specialization of the PET/CT
readers to specify or indicate their minimum qualification and experience.
All PET/CT scan readers are physicians trained to read scans using the standard
operating procedure in Supplementary File 5. The results of all reads from the 15 practice
scans at baseline and week 4 (30 scans total) must be within 2 standard deviations of the




Although the readers are not specifically blinded, they are generally not located at the
enrolling clinic site so have no access to any participant characteristics. The exception is
if the reader is located at the clinic site that enrolled that particular participant. The reader
randomization process precludes 2 readers from a single institution being assigned to the
same participant so this should mitigate any potential issues of bias.
Will the third reader who is to resolve any discrepant PET/CT scan be a more senior expert
or this is to be assumed?







We address the scenario in the clinical MOP sec 7.1 and 7.2 as it relates to week 16 but
the same principles apply at earlier time points. We do not respond to smear results,
whether positive or negative, as positive smears may persist beyond culture conversion.
The worst-case scenario would be a participant who at week 16 had no positive sputum
cultures (had already converted to negative), met study randomization criteria, and was
randomized to stop treatment at week 16. Subsequently, the week 16 (or earlier) culture
becomes positive. The participant would be called back for clinical evaluation and to
collect another sputum sample for confirmation. If the participant is clinically
asymptomatic, no further action is taken pending sputum culture positive confirmation. If
the participant has symptoms concerning for recurrent TB, the treating physician has
discretion to restart TB treatment for participant safety, with strong encouragement to
collect multiple sputum samples before treatment is re-initiated. A 2  positive sputum
culture is required to confirm study endpoint as recurrent TB.
‘PK-MIC sub study’ – kindly spell out PK-MIC at first mention. Although we believe it refers
to ‘pharmacokinetic’.
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